title: Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy.
abstract: We characterized lipid and lipoprotein changes associated with a lopinavir/ritonavir-containing regimen. We enrolled previously antiretroviral-naive patients participating in the Swiss HIV Cohort Study. Fasting blood samples (baseline) were retrieved retrospectively from stored frozen plasma and posttreatment (follow-up) samples were collected prospectively at two separate visits. Lipids and lipoproteins were analyzed at a single reference laboratory. Sixty-five patients had two posttreatment lipid profile measurements and nine had only one. Most of the measured lipids and lipoprotein plasma concentrations increased on lopinavir/ritonavir-based treatment. The percentage of patients with hypertriglyceridemia (TG >150 mg/dl) increased from 28/74 (38%) at baseline to 37/65 (57%) at the second follow-up. We did not find any correlation between lopinavir plasma levels and the concentration of triglycerides. There was weak evidence of an increase in small dense LDL-apoB during the first year of treatment but not beyond 1 year (odds ratio 4.5, 90% CI 0.7 to 29 and 0.9, 90% CI 0.5 to 1.5, respectively). However, 69% of our patients still had undetectable small dense LDL-apoB levels while on treatment. LDL-cholesterol increased by a mean of 17 mg/dl (90% CI -3 to 37) during the first year of treatment, but mean values remained below the cut-off for therapeutic intervention. Despite an increase in the majority of measured lipids and lipoproteins particularly in the first year after initiation, we could not detect an obvious increase of cardiovascular risk resulting from the observed lipid changes.
authors.affiliation: Division of Infectious Diseases, Hospital of Lugano, Switzerland .
authors.forename: L
authors.initials: L
authors.lastname: Magenta
authors.forename: S
authors.initials: S
authors.lastname: Dell-Kuster
authors.forename: W O
authors.initials: WO
authors.lastname: Richter
authors.forename: J
authors.initials: J
authors.lastname: Young
authors.forename: B
authors.initials: B
authors.lastname: Hasse
authors.forename: M
authors.initials: M
authors.lastname: Flepp
authors.forename: B
authors.initials: B
authors.lastname: Hirschel
authors.forename: P
authors.initials: P
authors.lastname: Vernazza
authors.forename: J
authors.initials: J
authors.lastname: Evison
authors.forename: M
authors.initials: M
authors.lastname: Cavassini
authors.forename: L A
authors.initials: LA
authors.lastname: Decosterd
authors.forename: H C
authors.initials: HC
authors.lastname: Bucher
authors.forename: E
authors.initials: E
authors.lastname: Bernasconi
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D011744:Pyrimidinones / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D018570:Risk Assessment; D019438:Ritonavir / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D019380:Anti-HIV Agents; D008055:Lipids; D008074:Lipoproteins; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir